The Merger (Schedule of company’s consolidated statement of operations and unaudited proforma information) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Business Acquisition [Line Items]
General and administrative expenses	$ 2,171,000	$ 1,380,000
Net loss	(5,078,000)	$ (3,739,000)
AmpliPhi Biosciences Corporation [Member]
Business Acquisition [Line Items]
Research and development expenses	122,000
General and administrative expenses	260,000
Net loss	$ 382,000